The US Department of Defense (DoD) is set to study the PLX-R18 cell therapy product as a treatment for long-term lung injuries caused by mustard gas exposure.

To this end, the DoD and the US Army Medical Research Institute of Chemical Defense (USAMRICD) have entered an additional collaboration agreement with placenta-based cell therapy products developer Pluristem Therapeutics for its PLX-R18 product.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Known as mustard gas, sulphur mustard is a chemical warfare agent that causes severe chemical burns in multiple organs and can lead to long-term lung damage.

PLX-R18 has so far been effective in recovering the bone marrow, leading to regeneration of progenitor cells and the three blood lineages, namely blood cells, red blood cells and platelets.

“Following the positive results with PLX-R18 in ARS, we believe that the cells have the potential to mitigate the deleterious effects of mustard gas.”

Pluristem Therapeutics co-CEO and president Yaky Yanay said: “Mustard gas injuries have both acute and long-term consequences.

“We believe that PLX-R18 has the potential to alleviate or prevent the devastating effects of both the acute and chronic injuries following mustard gas exposure.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Funded by the US National Institutes of Health (NIH), the new agreement is the second project selected by the defence department for Pluristem’s PLX-R18.

The DoD is also currently studying the effectiveness of PLX-R18 as a new medical countermeasure for Acute Radiation Syndrome (ARS) prior to exposure to high levels of radiation.

The study has been specifically designed to support the needs of the US Armed Forces.

Yanay added: “Following the positive results with PLX-R18 in ARS, we believe that the cells have the potential to mitigate the deleterious effects of mustard gas.

“Positive results from these studies may establish PLX-R18 as a medical countermeasure against a wide range of chemical, biological, radiological and nuclear (CBRN) threat agents.”

The two projects are part of the NIH-funded late-stage development of PLX-R18 to treat injuries that result from acute exposure to high levels of radiation.